Home
/
NewAmsterdam Pharma Co N.V.
/
Financials
/
Quarterly
NewAmsterdam Pharma Co N.V. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that NewAmsterdam Pharma Co N.V. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$348.0K
Nov 5, 2025
Q2
2025
Jun 30, 2025
$19.15M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$2.98M
May 8, 2025
Q3
2025
Sep 30, 2024
$29.11M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$2.28M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$1.40M
May 8, 2025
Q3
2024
Sep 30, 2023
$2.94M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$1.72M
Aug 7, 2024
Q1
2024
Mar 31, 2023
$8.63M
May 8, 2024
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($72.01M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($17.36M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($39.53M)
May 8, 2025
Q3
2025
Sep 30, 2024
($16.65M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($39.01M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($93.77M)
May 8, 2025
Q3
2024
Sep 30, 2023
($47.13M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($38.29M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($42.02M)
May 8, 2024
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($55.14M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($35.64M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($68.93M)
May 8, 2025
Q3
2025
Sep 30, 2024
($25.00M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($52.58M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($55.48M)
May 8, 2025
Q3
2024
Sep 30, 2023
($49.56M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($42.48M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($39.85M)
May 8, 2024